Clinical trial NCT03117361: Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Official title: Phase II Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Multiple Myeloma
Keywords: multiple myeloma
plitidepsin
Aplidin
Lead sponsor: PharmaMar
Sponsor class: INDUSTRY
First posted: 2017-04-17
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multi-center, open-label, single arm, non-comparative phase II trial, designed to evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with Multiple Myeloma (MM) double refractory to bortezomib and lenalidomide.

Detailed description: This is a multi-center, open-label, single arm, non-comparative phase II trial, designed to evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with MM double refractory to bortezomib and lenalidomide.The primary endpoint will be overall response rate (ORR), including stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR).

Approximately 64 evaluable patients will be needed for the evaluation of the primary endpoint, ORR.

An early futility analysis will be performed with the efficacy data collected from the first 20 evaluable patients. The futility analysis will commence once patient number 20 has completed two full treatment cycles. Patient recruitment will not be halted during the conduct of this futility analysis.

Eligibility criteria: Inclusion Criteria:

1. Patients must give written informed consent (IC) in accordance with institutional and local guidelines.
2. Age ≥ 18 years.
3. Patients must have a confirmed diagnosis of MM according to the Durie and Salmon criteria.
4. Patients must have measurable disease defined as any of the following:

   1. Serum M-protein ≥ 0.5 g/dL or ≥ 0.2 g/24-h urine light chain (UFLC) excretion.
   2. In patients who lack measureable M-protein in serum or urine, i.e., serum M-protein \< 0.5 g/dL and urine M-protein \< 0.2 g/24 h, serum free light chain (SFLC) levels are most informative. SFLC levels can be used only if the baseline SFLC ratio is abnormal (\<0.26 or \>1.65), indicating clonality. In addition, the baseline SFLC level must be ≥10 mg/dl of the appropriate involved light chain isotype.
   3. When applicable, measurable soft tissue plasmacytoma ≥ 2 cm, by either physical examination and/or applicable radiological evaluation (i.e., magnetic resonance imaging \[MRI\], computed tomography \[CT\]-scan).
5. Prior autologous and/or allogeneic hematopoietic stem cell transplantation (HSCT) patients are allowed. Patients must not have acute/chronic graft-versus-host disease (GVHD) or be receiving immunosuppressive therapy at least 90 days before the onset of treatment with the trial drug(s).
6. Patients must have received previous treatment with bortezomib and lenalidomide and be refractory to both.
7. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
8. Recovery to grade ≤ 1 from any non-hematological adverse event (AE) derived from previous treatment (if present, alopecia and peripheral neuropathy must be grade \<1).
9. Laboratory data:

   1. Hemoglobin ≥ 8 g/dL.
   2. Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 (1.0 x 109/L) (≥ 0.5 x 109/L if due to extensive bone marrow \[BM\] involvement by ≥ 50% of plasma cells in BM biopsy). Screening of ANC should be independent of granulocyte- and granulocyte/macrophage-colony stimulating factor (G-CSF and GM-CSF) support for at least one week and of pegylated G-CSF for at least two weeks.
   3. Platelet count ≥ 50,000/mm3 (50.0 x 109/L) for patients in whom \< 50% of the BM nucleated cells are plasma cells.
   4. Platelet count ≥ 25,000/mm3 (25.0 x 109/L) for patients in whom ≥ 50% of BM nucleated cells are plasma cells.
   5. Serum total bilirubin \< 1.5 x institutional upper limit of normal (ULN) (except when Gilbert syndrome is clearly documented and other liver function tests are within normal levels).
   6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x institutional ULN and alkaline phosphatase (AP) ≤ 2.5 x institutional ULN.
   7. Creatinine clearance (CrCl) \> 30 mL/min, measured or calculated according to Cockcroft and Gault's formula.
   8. Albumin ≥ 2.5 g/dl.
10. Evidence of non-childbearing status for women of childbearing potential (WOCBP): WOCBP must have a negative serum or urine pregnancy test within seven days prior to enrolment and must agree to use a highly effective contraceptive measure throughout the trial and during six months after treatment discontinuation. Male patients enrolled in the study should also use contraceptive methods during and after treatment discontinuation.
11. Left ventricular ejection fraction (LVEF) ≥ 45%.
12. Patients must have a BM assessment within three weeks prior to enrolment.

Exclusion Criteria:

1. Previous treatment with plitidepsin.
2. Active or metastatic primary malignancy other than MM.
3. Serious concomitant systemic disorders that would compromise the safety of the patient or the patient's ability to complete the trial, including the following specific conditions:

   1. Uncontrolled psychiatric illness or medical illness that the Investigator feels will compromise the patient's tolerance of the trial medication.
   2. Significant non-neoplastic liver disease.
   3. Uncontrolled endocrine diseases (i.e., requiring relevant changes in medication within the last month, or hospital admission within the last three months).
   4. Uncontrolled systemic infection.
   5. Acute infiltrative pulmonary and pericardial disease.
4. Other relevant cardiac conditions:

   1. Symptomatic arrhythmia (excluding anemia-related grade ≤ 2 sinusal tachycardia) or any arrhythmia requiring ongoing treatment, and/or prolonged grade ≥ 2 QT-QTc; or presence of unstable atrial fibrillation (according to the National Cancer Institute Common Terminology Criteria for the Classification of Adverse Events \[NCI-CTCAE\] v4.0). Patients on treatment for stable atrial fibrillation are allowed, provided they do not meet any other cardiac or prohibited drug exclusion criterion.
   2. History or presence of unstable angina, myocardial infarction, valvular heart disease, cardiac amyloidosis or congestive heart failure within the last 12 months.
   3. Uncontrolled arterial hypertension (≥ 150/100 mmHg) despite optimal medical therapy.
   4. Previous treatment with doxorubicin at cumulative doses of \> 400 mg/m², or equivalent.
5. History of hypersensitivity reactions and/or intolerance to bortezomib, polyoxyl 35 castor oil, mannitol, boron or dexamethasone.
6. Myopathy or any clinical situation that causes significant and persistent elevation of creatine phosphokinase (CPK) (\> 2.5 ULN) in two different determinations performed within one week of each other.
7. Grade ≥ 1 neuropathy (either bortezomib-related or not) according to NCI-CTCAE v4.0.
8. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patients' participation in this trial.
9. Pregnant and/or lactating women.
10. Known active human immunodeficiency virus (HIV) infection (HIV testing is not required unless infection is clinically suspected).
11. Active hepatitis B or C virus (HBV or HCV) infection.
12. Treatment with any Investigational Medicinal Product (IMP) in the 30 days before inclusion in the trial.
13. Concomitant medications that include corticosteroids, chemotherapy (CT), or other therapy that is or may be active against myeloma. Concurrent corticosteroids are allowed as an equivalent to a prednisone dose of ≤ 10 mg daily, administered as an antiemetic or as premedication for blood products.
14. Wash-out periods after the end of the previous therapy:

    1. Nitrosoureas must be discontinued six weeks prior to Cycle (C) 1, D1.
    2. Thirty days for other CTs and 15 days for other biological agents prior to C1 D1.
    3. Thirty days after the end of any prior radiation or radionuclide therapy (six weeks in the case of prior extensive external beam radiation, with more than 25% of BM distribution).
15. Plasma cell leukemia at the time of trial entry.
16. Disease-related symptomatic hypercalcemia despite optimal medical therapy.
17. Limitation of the patient's ability to comply with the treatment or follow-up protocol.
18. Contraindication to use steroids.

Primary outcomes:
measure: Overall Response
timeFrame: From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks
measure: Overall Response Rate
timeFrame: From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks
Secondary outcomes:
measure: Clinical Benefit Rate
timeFrame: From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks
measure: Disease Control Rate
timeFrame: From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks
measure: Duration of Response
timeFrame: From the date of first documentation of response to the date of disease progression, up to 100 weeks
measure: Time to Progression
timeFrame: From the date of the first infusion to the date of documented PD or death due to PD, up to 100 weeks
measure: Percentage of Participants With Progression Disease at 3 Months
timeFrame: From the date of the first infusion to the date of documented PD or death due to PD, up to 3 months
measure: Percentage of Participants With Progression Disease at 6 Months
timeFrame: From the date of the first infusion to the date of documented PD or death due to PD, up to 6 months
measure: Percentage of Participants With Progression Disease at 12 Months
timeFrame: From the date of the first infusion to the date of documented PD or death due to PD, up to 12 months
measure: Progression-free Survival
timeFrame: From the date of first drug administration to the date of documented PD, or death (of any cause), up to 100 weeks
measure: Percentage of Participants With Progression-free Survival at 3 Months
timeFrame: From the date of first drug administration to the date of documented PD, or death (of any cause), up to 3 months
measure: Percentage of Participants With Progression-free Survival at 6 Months
timeFrame: From the date of first drug administration to the date of documented PD, or death (of any cause), up to 6 months
measure: Percentage of Participants With Progression-free Survival at 12 Months
timeFrame: From the date of first drug administration to the date of documented PD, or death (of any cause), up to 12 months
measure: Event-free Survival
timeFrame: From the date of first drug administration to the date of onset of the first drug-related event leading to treatment discontinuation, documented PD or death, up to 100 weeks
measure: Percentage of Participants With Event-free Survival at 3 Months
timeFrame: From the date of first drug administration to the date of onset of the first drug-related event leading to treatment discontinuation, documented PD or death, up to 3 months
measure: Percentage of Participants With Event-free Survival at 6 Months
timeFrame: From the date of first drug administration to the date of onset of the first drug-related event leading to treatment discontinuation, documented PD or death, up to 6 months
measure: Percentage of Participants With Event-free Survival at 12 Months
timeFrame: From the date of first drug administration to the date of onset of the first drug-related event leading to treatment discontinuation, documented PD or death, up to 12 months
measure: Overall Survival
timeFrame: From the date of first drug administration to the date of death (of any cause) or last patient contact, up to 100 weeks
measure: Percentage of Participants With Overall Survival at 6 Months
timeFrame: From the date of first drug administration to the date of death (of any cause) or last patient contact, up to 6 months
measure: Percentage of Participants With Overall Survival at 12 Months
timeFrame: From the date of first drug administration to the date of death (of any cause) or last patient contact, up to 12 months
Other outcomes:
Locations:
city: Lille
country: France
facility: CHRU de Lille - Hôpital Claude Huriez
city: Villejuif
country: France
facility: Institut Gustave Roussy
city: Catania
country: Italy
facility: Policlinico Vittorio Emanuele Hospital
city: Meldola
country: Italy
facility: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
city: Torino
country: Italy
facility: Azienda Ospedaliera Città della Salute e della Scienza di Torino
city: Badalona
country: Spain
facility: Hospital Universitario Germans Trias i Pujol
state: Barcelona
city: Pamplona
country: Spain
facility: Clinica Universidad de Navarra
state: Navarra
city: Girona
country: Spain
facility: Institut Català d´Oncologia Girona
city: Hospitalet de Llobregat
country: Spain
facility: Institut Català d´Oncologia L´Hospitalet
city: Murcia
country: Spain
facility: Hospital General Universitario J.M. Morales Meseguer
city: Salamanca
country: Spain
facility: Hospital Universitario de Salamanca
city: Santiago De Compostela
country: Spain
facility: Complexo Hospitalario Universitario de Santiago
city: Sevilla
country: Spain
facility: Complejo Hospitalario Regional Virgen Del Rocio
Study officials:
References: